[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.191.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 140
Citations 0
Comment & Response
May 2, 2019

Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin—In Reply

Author Affiliations
  • 1Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston
  • 4Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston Massachusetts
  • 5Broad Institute, Boston Massachusetts
  • 6Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston Massachusetts
JAMA Oncol. 2019;5(6):911-912. doi:10.1001/jamaoncol.2019.0630

In Reply We thank Chien and colleagues for their interest in our study of aspirin use and incident hepatocellular carcinoma (HCC) in the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts.1 The authors argue that a disproportionate number of the patients with HCC were women; however, the number of cases reflects our underlying population, which was composed of 87 507 women (Nurses’ Health Study) and 45 864 men (Health Professionals Follow-up Study). Indeed, our sex-specific cumulative incidence of HCC was 2 per 100 000 women and 5 per 100 000 men, which corresponds to population-based estimates for the time period of our study (1980-2012 in women; 1986-2012 in men).2

×